New Mayo Clinic MRI technology enables noninvasive liver diagnoses

May 22, 2007

ROCHESTER, Minn. -- Two recent Mayo Clinic studies have found that magnetic resonance elastography (MRE), a new imaging technique invented at Mayo Clinic, is an accurate tool for non-invasive diagnosis of liver diseases. The findings will be presented this week at the International Society for Magnetic Resonance in Medicine Annual Meeting in Berlin, Germany, and Digestive Disease Week 2007 in Washington, D.C.

The liver responds to many diseases that damage its cells by developing scar tissue or fibrosis. MRE uses a modified form of magnetic resonance imaging (MRI) to accurately measure the hardness or elasticity of the liver. By applying vibrations to the liver, MRE obtains pictures of the mechanical waves passing through the organ. The wave pictures are then processed to generate a quantitative image of tissue stiffness.

"Healthy liver tissue is very soft, while a liver with fibrosis is firmer, and a liver with cirrhosis is almost rock-hard," says Richard Ehman, M.D., lead researcher on the MRE project. "If detected early, fibrosis of the liver can be treated, but once the disease has progressed to cirrhosis, the condition is irreversible."

Dr. Ehman and his imaging research team collaborated with Mayo Clinic gastroenterologists to study whether MRE could provide reliable and accurate diagnoses in patients with varying degrees of liver disease.

One study involved MRE examinations of 57 individuals with chronic liver disease and 20 healthy volunteers. The researchers confirmed that MRE accurately detects fibrosis with high sensitivity and specificity. Researchers also found that steatosis, which is deposits of fatty acids and triglycerides in liver cells and a common condition in patients with liver disease, did not interfere with detection of fibrosis with MRE.

"Based on this research, we are now using MRE examinations in select patients to determine liver stiffness and assess the need for liver biopsies," says Jayant Talwalkar, M.D., a Mayo Clinic gastroenterologist and an investigator on the MRE studies. "More than 170 million people in the world are known to have hepatitis C, and nearly one-fourth of those will develop severe liver fibrosis. MRE can help us noninvasively identify fibrosis in this large patient population."

A second study looked at whether MRE can accurately measure portal hypertension, or high blood pressure in the portal vein that carries blood from the digestive track to the liver, usually as a result of cirrhosis of the liver. This study involved 35 individuals with varying degrees of chronic liver disease and 12 healthy volunteers. Researchers studied MRE examinations of liver and spleen stiffness and found that a highly significant correlation exists between liver and spleen stiffness in patients with portal hypertension. However, the validity of spleen stiffness as a noninvasive measure of portal venous pressure requires further study.

According to Dr. Ehman, many diseases cause the properties of tissue to change and will be likely candidates for diagnosis using MRE in the future. His research team is exploring the use of MRE in detecting breast cancer and Alzheimer's disease.
-end-
VIDEO ALERT: Sound bites from a subject expert are available through Pathfire's Digital Media Gateway DMG). See end of this release for details.

This research was funded in part by the National Institutes of Health. Co-authors of these studies include Meng Yin; Roger Grimm; Phillip Rossman; Armando Manduca, Ph.D.; Patrick Kamath, M.D. and Dr. Ehman; all from Mayo Clinic's campus in Rochester; and Anthony Romano, Ph.D., of the Naval Research Laboratory in Washington, D.C.

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

Mayo Clinic uses Pathfire's Digital Media Gateway (DMG) for video distribution, streamlining our services and providing content that is easily accessible. On the DMG main page, look for the Mayo Clinic branded page in the left navbar, or click on the VNF Master Locator and search for mayoclinic0071. If you have questions or problems in locating the story, contact Pathfire Customer Support at 888-345-0489 or support@pathfire.com. If you do not have access to Pathfire's DMG, and would like access to Mayo Clinic's video resources by satellite or other means, please call 507-266-9031 or e-mail: mona.laurie@mayo.edu.

Mayo Clinic

Related Liver Disease Articles from Brightsurf:

Fatty liver disease despite a normal weight
Researchers from the University of Tsukuba found significant differences in the clinical presentation of non-obese patients with non-alcoholic fatty liver disease (NAFLD) based on their sex and body mass index.

Sobering reminder about liver disease
Alcohol's popularity and its central place in socialising in Australia obscures the dangers of excessive drinking and possible liver disease, Flinders University experts warn.

Giant leap in diagnosing liver disease
A collaborative team of Salk Institute and UC San Diego scientists have created a novel microbiome-based diagnostic tool that, with the accuracy of the best physicians, quickly and inexpensively identifies liver fibrosis and cirrhosis over 90 percent of the time in human patients.

Link between liver and heart disease could lead to new therapeutics
A newly published study of flies found that protecting liver function also preserves heart health.

Fatty liver disease is underdiagnosed in the US
According to an analysis published in Alimentary Pharmacology & Therapeutics, nonalcoholic fatty liver disease (NAFLD) is grossly underdiagnosed in the United States.

Possible new treatment strategy for fatty liver disease
Researchers at Karolinska Institutet in Sweden have identified a molecular pathway that when silenced could restore the normal function of immune cells in people with fatty liver disease.

Longevity protein SIRT6 also protects against fatty liver and fatty liver disease
SIRT6 regulates fat metabolism by activating another protein called peroxisome proliferator-activated receptor alpha (PPAR-alpha).

Fresh insights could lead to new treatments for liver disease
The fight against liver disease could be helped by the discovery of cells that cause liver scarring.

Better methods needed for predicting risk of liver disease
While blood samples can reliably identify people with a low risk of developing severe liver disease, better methods are needed in primary care for identifying people in most need of care.

Lab-on-a-chip may help identify new treatments for liver disease
Investigators have developed a 'lab on a chip' technology that can simulate different levels of non-alcoholic fatty liver disease progression.

Read More: Liver Disease News and Liver Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.